{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:03:21Z","timestamp":1790388201812,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:00:00Z","timestamp":1470355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011781","name":"Shriners Hospital for Children","doi-asserted-by":"crossref","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100011781","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["24707"],"award-info":[{"award-number":["24707"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00198-016-3723-3","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T22:09:46Z","timestamp":1470348586000},"page":"3427-3437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":169,"title":["Osteogenesis imperfecta in children and adolescents\u2014new developments in diagnosis and treatment"],"prefix":"10.1007","volume":"27","author":[{"given":"P.","family":"Trejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"3723_CR1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC (2016) Osteogenesis imperfecta. Lancet 387:1657\u20131671","journal-title":"Lancet"},{"key":"3723_CR2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrrheum.2015.48","volume":"11","author":"G Hendrickx","year":"2015","unstructured":"Hendrickx G, Boudin E, Van Hul W (2015) A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol 11:462\u2013474","journal-title":"Nat Rev Rheumatol"},{"key":"3723_CR3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.tem.2016.03.006","volume":"27","author":"F Rivadeneira","year":"2016","unstructured":"Rivadeneira F, Makitie O (2016) Osteoporosis and bone mass disorders: from gene pathways to treatments. Trends Endocrinol Metab 27:262\u2013281","journal-title":"Trends Endocrinol Metab"},{"key":"3723_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11914-014-0225-0","volume":"12","author":"A Biggin","year":"2014","unstructured":"Biggin A, Munns CF (2014) Osteogenesis imperfecta: diagnosis and treatment. Curr Osteoporos Rep 12:279\u2013288","journal-title":"Curr Osteoporos Rep"},{"key":"3723_CR5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.pcl.2014.08.010","volume":"61","author":"J Harrington","year":"2014","unstructured":"Harrington J, Sochett E, Howard A (2014) Update on the evaluation and treatment of osteogenesis imperfecta. Pediatr Clin North Am 61:1243\u20131257","journal-title":"Pediatr Clin North Am"},{"key":"3723_CR6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10354-015-0361-x","volume":"165","author":"H Hoyer-Kuhn","year":"2015","unstructured":"Hoyer-Kuhn H, Netzer C, Semler O (2015) Osteogenesis imperfecta: pathophysiology and treatment. Wien Med Wochenschr 165:278\u2013284","journal-title":"Wien Med Wochenschr"},{"key":"3723_CR7","doi-asserted-by":"crossref","unstructured":"Shaker JL, Albert C, Fritz J, Harris G (2015) Recent developments in osteogenesis imperfecta. F1000Res 4:681","DOI":"10.12688\/f1000research.6398.1"},{"key":"3723_CR8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"3723_CR9","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/ajmg.a.37365","volume":"167A","author":"L Bonafe","year":"2015","unstructured":"Bonafe L, Cormier-Daire V, Hall C et al (2015) Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 167A:2869\u20132892","journal-title":"Am J Med Genet A"},{"key":"3723_CR10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"key":"3723_CR11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30\u201338","journal-title":"J Bone Miner Res"},{"key":"3723_CR12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","volume":"31","author":"LM Ward","year":"2002","unstructured":"Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31:12\u201318","journal-title":"Bone"},{"key":"3723_CR13","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","volume":"164A","author":"FS Dijk Van","year":"2014","unstructured":"Van Dijk FS, Sillence DO (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 164A:1470\u20131481","journal-title":"Am J Med Genet A"},{"key":"3723_CR14","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0021-9258(18)89655-7","volume":"260","author":"J Bonadio","year":"1985","unstructured":"Bonadio J, Holbrook KA, Gelinas RE, Jacob J, Byers PH (1985) Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta. J Biol Chem 260:1734\u20131742","journal-title":"J Biol Chem"},{"key":"3723_CR15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","volume":"23","author":"K Lindahl","year":"2015","unstructured":"Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren O, Kindmark A (2015) Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet 23:1042\u20131050","journal-title":"Eur J Hum Genet"},{"key":"3723_CR16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajmg.c.31466","volume":"169","author":"LM Bronicki","year":"2015","unstructured":"Bronicki LM, Stevenson RE, Spranger JW (2015) Beyond osteogenesis imperfecta: causes of fractures during infancy and childhood. Am J Med Genet C: Semin Med Genet 169:314\u2013327","journal-title":"Am J Med Genet C: Semin Med Genet"},{"key":"3723_CR17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajmg.c.31459","volume":"169","author":"MG Pepin","year":"2015","unstructured":"Pepin MG, Byers PH (2015) What every clinical geneticist should know about testing for osteogenesis imperfecta in suspected child abuse cases. Am J Med Genet C: Semin Med Genet 169:307\u2013313","journal-title":"Am J Med Genet C: Semin Med Genet"},{"key":"3723_CR18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/ejhg.2009.242","volume":"18","author":"F Rauch","year":"2010","unstructured":"Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. Eur J Hum Genet 18:642\u2013647","journal-title":"Eur J Hum Genet"},{"key":"3723_CR19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jped.2014.05.003","volume":"90","author":"ER Valadares","year":"2014","unstructured":"Valadares ER, Carneiro TB, Santos PM, Oliveira AC, Zabel B (2014) What is new in genetics and osteogenesis imperfecta classification? J Pediatr (Rio J) 90:536\u2013541","journal-title":"J Pediatr (Rio J)"},{"key":"3723_CR20","first-page":"638","volume":"55","author":"MC Willing","year":"1994","unstructured":"Willing MC, Deschenes SP, Scott DA, Byers PH, Slayton RL, Pitts SH, Arikat H, Roberts EJ (1994) Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Hum Genet 55:638\u2013647","journal-title":"Am J Hum Genet"},{"key":"3723_CR21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/humu.22812","volume":"36","author":"J Schleit","year":"2015","unstructured":"Schleit J, Bailey SS, Tran T, Chen D, Stowers S, Schwarze U, Byers PH (2015) Molecular outcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the proalpha1(I) chains of type I procollagen. Hum Mutat 36:728\u2013739","journal-title":"Hum Mutat"},{"key":"3723_CR22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-015-0066-6","volume":"98","author":"G Bardai","year":"2016","unstructured":"Bardai G, Lemyre E, Moffatt P, Palomo T, Glorieux FH, Tung J, Ward L, Rauch F (2016) Osteogenesis imperfecta type I caused by COL1A1 deletions. Calcif Tissue Int 98:76\u201384","journal-title":"Calcif Tissue Int"},{"key":"3723_CR23","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.1942","volume":"28","author":"IM Ben Amor","year":"2013","unstructured":"Ben Amor IM, Roughley P, Glorieux FH, Rauch F (2013) Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res 28:2001\u20132007","journal-title":"J Bone Miner Res"},{"key":"3723_CR24","doi-asserted-by":"crossref","first-page":"19259","DOI":"10.1074\/jbc.M414698200","volume":"280","author":"WA Cabral","year":"2005","unstructured":"Cabral WA, Makareeva E, Colige A, Letocha AD, Ty JM, Yeowell HN, Pals G, Leikin S, Marini JC (2005) Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta\/Ehlers-Danlos syndrome by interference with N-propeptide processing. J Biol Chem 280:19259\u201319269","journal-title":"J Biol Chem"},{"key":"3723_CR25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/humu.20429","volume":"28","author":"JC Marini","year":"2007","unstructured":"Marini JC, Forlino A, Cabral WA et al (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 28:209\u2013221","journal-title":"Hum Mutat"},{"key":"3723_CR26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/hmg\/ddu471","volume":"24","author":"S Fahiminiya","year":"2015","unstructured":"Fahiminiya S, Al-Jallad H, Majewski J, Palomo T, Moffatt P, Roschger P, Klaushofer K, Glorieux FH, Rauch F (2015) A polyadenylation site variant causes transcript-specific BMP1 deficiency and frequent fractures in children. Hum Mol Genet 24:516\u2013524","journal-title":"Hum Mol Genet"},{"key":"3723_CR27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1308223","volume":"369","author":"FS Dijk van","year":"2013","unstructured":"van Dijk FS, Zillikens MC, Micha D et al (2013) PLS3 mutations in X-linked osteoporosis with fractures. N Engl J Med 369:1529\u20131536","journal-title":"N Engl J Med"},{"key":"3723_CR28","doi-asserted-by":"crossref","unstructured":"Zarate YA, Clingenpeel R, Sellars EA, Tang X, Kaylor JA, Bosanko K, Linam LE, Byers PH (2016) COL1A1 and COL1A2 sequencing results in cohort of patients undergoing evaluation for potential child abuse. Am J Med Genet A","DOI":"10.1002\/ajmg.a.37664"},{"key":"3723_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jmedgenet-2012-101307","volume":"50","author":"F Rauch","year":"2013","unstructured":"Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund AM, Ramirez N, Fahiminiya S, Majewski J, Glorieux FH (2013) Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients. J Med Genet 50:21\u201324","journal-title":"J Med Genet"},{"key":"3723_CR30","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/jbmr.1983","volume":"28","author":"M Grover","year":"2013","unstructured":"Grover M, Campeau PM, Lietman CD, Lu JT, Gibbs RA, Schlesinger AE, Lee BH (2013) Osteogenesis imperfecta without features of type V caused by a mutation in the IFITM5 gene. J Bone Miner Res 28:2333\u20132337","journal-title":"J Bone Miner Res"},{"key":"3723_CR31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1359\/jbmr.070418","volume":"22","author":"MS Cheung","year":"2007","unstructured":"Cheung MS, Glorieux FH, Rauch F (2007) Natural history of hyperplastic callus formation in osteogenesis imperfecta type V. J Bone Miner Res 22:1181\u20131186","journal-title":"J Bone Miner Res"},{"key":"3723_CR32","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.2106\/JBJS.F.01287","volume":"89","author":"AM Fassier","year":"2007","unstructured":"Fassier AM, Rauch F, Aarabi M, Janelle C, Fassier F (2007) Radial head dislocation and subluxation in osteogenesis imperfecta. J Bone Joint Surg Am 89:2694\u20132704","journal-title":"J Bone Joint Surg Am"},{"key":"3723_CR33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jbmr.220","volume":"26","author":"MS Cheung","year":"2011","unstructured":"Cheung MS, Arponen H, Roughley P, Azouz ME, Glorieux FH, Waltimo-Siren J, Rauch F (2011) Cranial base abnormalities in osteogenesis imperfecta: phenotypic and genotypic determinants. J Bone Miner Res 26:405\u2013413","journal-title":"J Bone Miner Res"},{"key":"3723_CR34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ajmg.a.32653","volume":"149A","author":"E Faqeih","year":"2009","unstructured":"Faqeih E, Roughley P, Glorieux FH, Rauch F (2009) Osteogenesis imperfecta type III with intracranial hemorrhage and brachydactyly associated with mutations in exon 49 of COL1A2. Am J Med Genet A 149A:461\u2013465","journal-title":"Am J Med Genet A"},{"key":"3723_CR35","unstructured":"Kishta W, Abduljabbar FH, Gdalevitch M, Rauch F, Hamdy R, Fassier F (2015) Hip dysplasia in children with osteogenesis imperfecta: association with collagen type I C-propeptide mutations. J Pediatr Orthop"},{"key":"3723_CR36","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12:183\u2013188","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"3723_CR37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O (2014) Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis 9:145","journal-title":"Orphanet J Rare Dis"},{"key":"3723_CR38","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00198-013-2290-0","volume":"24","author":"G Sule","year":"2013","unstructured":"Sule G, Campeau PM, Zhang VW et al (2013) Next-generation sequencing for disorders of low and high bone mineral density. Osteoporos Int 24:2253\u20132259","journal-title":"Osteoporos Int"},{"key":"3723_CR39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00223-014-9897-9","volume":"95","author":"F Rauch","year":"2014","unstructured":"Rauch F, Lalic L, Glorieux FH, Moffatt P, Roughley P (2014) Targeted sequencing of a pediatric metabolic bone gene panel using a desktop semiconductor next-generation sequencer. Calcif Tissue Int 95:323\u2013331","journal-title":"Calcif Tissue Int"},{"key":"3723_CR40","doi-asserted-by":"crossref","unstructured":"Bardai G, Moffatt P, Glorieux FH, Rauch F DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum..Osteoporos Int. In press","DOI":"10.1007\/s00198-016-3709-1"},{"key":"3723_CR41","first-page":"171","volume":"15","author":"A Pouliot-Laforte","year":"2015","unstructured":"Pouliot-Laforte A, Veilleux LN, Rauch F, Lemay M (2015) Physical activity in youth with osteogenesis imperfecta type I. J Musculoskelet Neuronal Interact 15:171\u2013176","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"Suppl 5","key":"3723_CR42","first-page":"8","volume":"68","author":"FH Glorieux","year":"2007","unstructured":"Glorieux FH (2007) Treatment of osteogenesis imperfecta: who, why, what? Horm Res 68(Suppl 5):8\u201311","journal-title":"Horm Res"},{"key":"3723_CR43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2016.02.015","volume":"87","author":"K Lindahl","year":"2016","unstructured":"Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Soderhall S, Ljunggren O, Astrom E (2016) Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate. Bone 87:11\u201318","journal-title":"Bone"},{"key":"3723_CR44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000351374","volume":"79","author":"MB Alcausin","year":"2013","unstructured":"Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, Engelbert RH, Sillence DO, Munns CF (2013) Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr 79:333\u2013340","journal-title":"Horm Res Paediatr"},{"key":"3723_CR45","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1530\/EJE-14-0865","volume":"173","author":"V Saraff","year":"2015","unstructured":"Saraff V, Hogler W (2015) Osteoporosis in children: diagnosis and management. Eur J Endocrinol 173:R185\u2013R197","journal-title":"Eur J Endocrinol"},{"key":"3723_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11914-016-0299-y","volume":"14","author":"IH Thomas","year":"2016","unstructured":"Thomas IH, DiMeglio LA (2016) Advances in the classification and treatment of osteogenesis imperfecta. Curr Osteoporos Rep 14:1\u20139","journal-title":"Curr Osteoporos Rep"},{"key":"3723_CR47","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/jbmr.413","volume":"26","author":"T Edouard","year":"2011","unstructured":"Edouard T, Glorieux FH, Rauch F (2011) Relationship between vitamin D status and bone mineralization, mass, and metabolism in children with osteogenesis imperfecta: histomorphometric study. J Bone Miner Res 26:2245\u20132251","journal-title":"J Bone Miner Res"},{"key":"3723_CR48","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1210\/jc.2011-1480","volume":"96","author":"T Edouard","year":"2011","unstructured":"Edouard T, Glorieux FH, Rauch F (2011) Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta. J Clin Endocrinol Metab 96:3193\u20133198","journal-title":"J Clin Endocrinol Metab"},{"key":"3723_CR49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/07315724.2015.1057776","volume":"35","author":"MB Zambrano","year":"2016","unstructured":"Zambrano MB, Brizola E, Pinheiro B, Vanz AP, Mello ED, Felix TM (2016) Study of the determinants of vitamin D status in pediatric patients with osteogenesis imperfecta. J Am Coll Nutr 35:339\u2013345","journal-title":"J Am Coll Nutr"},{"key":"3723_CR50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2016.02.013","volume":"86","author":"L Plante","year":"2016","unstructured":"Plante L, Veilleux LN, Glorieux FH, Weiler H, Rauch F (2016) Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: a randomized controlled trial. Bone 86:36\u201342","journal-title":"Bone"},{"key":"3723_CR51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","volume":"16","author":"JP Devogelaer","year":"1987","unstructured":"Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360\u2013363","journal-title":"Skeletal Radiol"},{"key":"3723_CR52","first-page":"Cd005088","volume":"7","author":"K Dwan","year":"2014","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2014) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 7:Cd005088","journal-title":"Cochrane Database Syst Rev"},{"key":"3723_CR53","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30:929\u2013933","journal-title":"J Bone Miner Res"},{"key":"3723_CR54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","volume":"84","author":"EB Rijks","year":"2015","unstructured":"Rijks EB, Bongers BC, Vlemmix MJ, Boot AM, van Dijk AT, Sakkers RJ, van Brussel M (2015) Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review. Horm Res Paediatr 84:26\u201342","journal-title":"Horm Res Paediatr"},{"key":"3723_CR55","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1359\/jbmr.091109","volume":"25","author":"F Rauch","year":"2010","unstructured":"Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 25:1367\u20131374","journal-title":"J Bone Miner Res"},{"key":"3723_CR56","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293\u20131299","journal-title":"J Clin Invest"},{"key":"3723_CR57","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","volume":"39","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH (2006) Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39:901\u2013906","journal-title":"Bone"},{"key":"3723_CR58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000331128","volume":"76","author":"O Semler","year":"2011","unstructured":"Semler O, Beccard R, Palmisano D, Demant A, Fricke O, Schoenau E, Koerber F (2011) Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. Horm Res Paediatr 76:321\u2013327","journal-title":"Horm Res Paediatr"},{"key":"3723_CR59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/adc.2006.096552","volume":"92","author":"E Astrom","year":"2007","unstructured":"Astrom E, Jorulf H, Soderhall S (2007) Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 92:332\u2013338","journal-title":"Arch Dis Child"},{"key":"3723_CR60","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","volume":"86","author":"E Astrom","year":"2002","unstructured":"Astrom E, Soderhall S (2002) Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356\u2013364","journal-title":"Arch Dis Child"},{"key":"3723_CR61","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","volume":"30","author":"T Palomo","year":"2015","unstructured":"Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30:2150\u20132157","journal-title":"J Bone Miner Res"},{"key":"3723_CR62","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","volume":"382","author":"N Bishop","year":"2013","unstructured":"Bishop N, Adami S, Ahmed SF et al (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382:1424\u20131432","journal-title":"Lancet"},{"key":"3723_CR63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355\u2013364","journal-title":"J Clin Endocrinol Metab"},{"key":"3723_CR64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bone.2016.02.018","volume":"86","author":"A Sato","year":"2016","unstructured":"Sato A, Ouellet J, Muneta T, Glorieux FH, Rauch F (2016) Scoliosis in osteogenesis imperfecta caused by COL1A1\/COL1A2 mutations\u2014genotype-phenotype correlations and effect of bisphosphonate treatment. Bone 86:53\u201357","journal-title":"Bone"},{"key":"3723_CR65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2106\/JBJS.L.01596","volume":"96","author":"AK Anissipour","year":"2014","unstructured":"Anissipour AK, Hammerberg KW, Caudill A, Kostiuk T, Tarima S, Zhao HS, Krzak JJ, Smith PA (2014) Behavior of scoliosis during growth in children with osteogenesis imperfecta. J Bone Joint Surg Am 96:237\u2013243","journal-title":"J Bone Joint Surg Am"},{"key":"3723_CR66","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427\u20131431","journal-title":"Lancet"},{"key":"3723_CR67","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947\u2013952","journal-title":"N Engl J Med"},{"key":"3723_CR68","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jpeds.2015.10.058","volume":"169","author":"T Palomo","year":"2016","unstructured":"Palomo T, Glorieux FH, Schoenau E, Rauch F (2016) Body composition in children and adolescents with osteogenesis imperfecta. J Pediatr 169:232\u2013237","journal-title":"J Pediatr"},{"key":"3723_CR69","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bone.2005.06.007","volume":"37","author":"F Rauch","year":"2005","unstructured":"Rauch F, Land C, Cornibert S, Schoenau E, Glorieux FH (2005) High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone 37:634\u2013641","journal-title":"Bone"},{"key":"3723_CR70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2014.05.022","volume":"66","author":"C Albert","year":"2014","unstructured":"Albert C, Jameson J, Smith P, Harris G (2014) Reduced diaphyseal strength associated with high intracortical vascular porosity within long bones of children with osteogenesis imperfecta. Bone 66:121\u2013130","journal-title":"Bone"},{"key":"3723_CR71","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bone.2006.02.071","volume":"39","author":"M Weber","year":"2006","unstructured":"Weber M, Roschger P, Fratzl-Zelman N, Schoberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K (2006) Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 39:616\u2013622","journal-title":"Bone"},{"key":"3723_CR72","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.apmr.2015.06.006","volume":"96","author":"K Montpetit","year":"2015","unstructured":"Montpetit K, Palomo T, Glorieux FH, Fassier F, Rauch F (2015) Multidisciplinary treatment of severe osteogenesis imperfecta: functional outcomes at skeletal maturity. Arch Phys Med Rehabil 96:1834\u20131839","journal-title":"Arch Phys Med Rehabil"},{"key":"3723_CR73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1592\/phco.24.2.195.33143","volume":"24","author":"RE Robinson","year":"2004","unstructured":"Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD (2004) Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 24:195\u2013197","journal-title":"Pharmacotherapy"},{"key":"3723_CR74","first-page":"3049","volume":"124","author":"M Li","year":"2011","unstructured":"Li M, Xia WB, Xing XP et al (2011) Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta. Chin Med J (Engl) 124:3049\u20133053","journal-title":"Chin Med J (Engl)"},{"key":"3723_CR75","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","volume":"41","author":"CF Munns","year":"2007","unstructured":"Munns CF, Rajab MH, Hong J, Briody J, Hogler W, McQuade M, Little DG, Cowell CT (2007) Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 41:366\u2013370","journal-title":"Bone"},{"key":"3723_CR76","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1210\/jc.2015-2680","volume":"100","author":"S George","year":"2015","unstructured":"George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA (2015) Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience. J Clin Endocrinol Metab 100:4163\u20134171","journal-title":"J Clin Endocrinol Metab"},{"key":"3723_CR77","doi-asserted-by":"crossref","unstructured":"Kumar C, Panigrahi I, Somasekhara Aradhya A, Meena BL, Khandelwal N (2016) Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children. J Pediatr Endocrinol Metab","DOI":"10.1515\/jpem-2015-0351"},{"key":"3723_CR78","doi-asserted-by":"crossref","unstructured":"Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud RJ, Tebben PJ (2016) Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. Osteoporos Int","DOI":"10.1007\/s00198-016-3528-4"},{"key":"3723_CR79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2004.03.008","volume":"35","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Mier RJ, Glorieux FH (2004) Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35:231\u2013234","journal-title":"Bone"},{"key":"3723_CR80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/PRM-140284","volume":"7","author":"JA Olson","year":"2014","unstructured":"Olson JA (2014) Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report. J Pediatr Rehabil Med 7:155\u2013158","journal-title":"J Pediatr Rehabil Med"},{"key":"3723_CR81","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5037\/jomr.2013.4401","volume":"4","author":"AA Hennedige","year":"2013","unstructured":"Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV (2013) Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res 4:e1","journal-title":"J Oral Maxillofac Res"},{"key":"3723_CR82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/adj.12140","volume":"59","author":"RN Bhatt","year":"2014","unstructured":"Bhatt RN, Hibbert SA, Munns CF (2014) The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J 59:9\u201319","journal-title":"Aust Dent J"},{"key":"3723_CR83","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779\u20131786","journal-title":"J Bone Miner Res"},{"key":"3723_CR84","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jbmr.2486","volume":"30","author":"EA Anam","year":"2015","unstructured":"Anam EA, Rauch F, Glorieux FH, Fassier F, Hamdy R (2015) Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment. J Bone Miner Res 30:1362\u20131368","journal-title":"J Bone Miner Res"},{"key":"3723_CR85","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/17453674.2012.729183","volume":"83","author":"RP Meier","year":"2012","unstructured":"Meier RP, Ing Lorenzini K, Uebelhart B, Stern R, Peter RE, Rizzoli R (2012) Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta\u2014a case report. Acta Orthop 83:548\u2013550","journal-title":"Acta Orthop"},{"key":"3723_CR86","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1210\/jc.2012-4195","volume":"98","author":"KN Manolopoulos","year":"2013","unstructured":"Manolopoulos KN, West A, Gittoes N (2013) The paradox of prevention\u2014bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta. J Clin Endocrinol Metab 98:871\u2013872","journal-title":"J Clin Endocrinol Metab"},{"key":"3723_CR87","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.4158\/EP14141.CR","volume":"20","author":"J Holm","year":"2014","unstructured":"Holm J, Eiken P, Hyldstrup L, Jensen JE (2014) Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide. Endocr Pract 20:e187\u2013e190","journal-title":"Endocr Pract"},{"key":"3723_CR88","first-page":"278","volume":"12","author":"I Etxebarria-Foronda","year":"2015","unstructured":"Etxebarria-Foronda I, Carpintero P (2015) An atypical fracture in male patient with osteogenesis imperfecta. Clin Cases Miner Bone Metab 12:278\u2013281","journal-title":"Clin Cases Miner Bone Metab"},{"key":"3723_CR89","doi-asserted-by":"crossref","unstructured":"Vasanwala RF, Sanghrajka A, Bishop NJ, Hogler W (2016) Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating? J Bone Miner Res","DOI":"10.1002\/jbmr.2805"},{"key":"3723_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"3723_CR91","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/01241398-199103000-00008","volume":"11","author":"JA Dent","year":"1991","unstructured":"Dent JA, Paterson CR (1991) Fractures in early childhood: osteogenesis imperfecta or child abuse? J Pediatr Orthop 11:184\u2013186","journal-title":"J Pediatr Orthop"},{"key":"3723_CR92","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O (2016) Safety and efficacy of denosumab in children with osteogenesis imperfecta\u2014a first prospective trial. J Musculoskelet Neuronal Interact 16:24\u201332","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"3723_CR93","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1210\/jc.2013-3081","volume":"99","author":"HD Wang","year":"2014","unstructured":"Wang HD, Boyce AM, Tsai JY, Gafni RI, Farley FA, Kasa-Vubu JZ, Molinolo AA, Collins MT (2014) Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab 99:891\u2013897","journal-title":"J Clin Endocrinol Metab"},{"key":"3723_CR94","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","volume":"19","author":"F Rauch","year":"2004","unstructured":"Rauch F, Travers R, Munns C, Glorieux FH (2004) Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 19:1191\u20131193","journal-title":"J Bone Miner Res"},{"key":"3723_CR95","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","volume":"27","author":"AM Boyce","year":"2012","unstructured":"Boyce AM, Chong WH, Yao J et al (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27:1462\u20131470","journal-title":"J Bone Miner Res"},{"key":"3723_CR96","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","volume":"34","author":"N Setsu","year":"2016","unstructured":"Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A, Horiuchi K (2016) Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab 34:118\u2013122","journal-title":"J Bone Miner Metab"},{"key":"3723_CR97","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES, Shapiro J, Veith S et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124:491\u2013498","journal-title":"J Clin Invest"},{"key":"3723_CR98","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","volume":"28","author":"BP Sinder","year":"2013","unstructured":"Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2013) Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 28:73\u201380","journal-title":"J Bone Miner Res"},{"key":"3723_CR99","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","volume":"29","author":"CM Jacobsen","year":"2014","unstructured":"Jacobsen CM, Barber LA, Ayturk UM et al (2014) Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res 29:2297\u20132306","journal-title":"J Bone Miner Res"},{"key":"3723_CR100","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","volume":"31","author":"I Grafe","year":"2016","unstructured":"Grafe I, Alexander S, Yang T et al (2016) Sclerostin antibody treatment improves the bone phenotype of Crtap(\u2212\/\u2212) mice, a model of recessive osteogenesis imperfecta. J Bone Miner Res 31:1030\u20131040","journal-title":"J Bone Miner Res"},{"key":"3723_CR101","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","volume":"66","author":"A Roschger","year":"2014","unstructured":"Roschger A, Roschger P, Keplingter P, Klaushofer K, Abdullah S, Kneissel M, Rauch F (2014) Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 66:182\u2013188","journal-title":"Bone"},{"key":"3723_CR102","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","volume":"26","author":"F Rauch","year":"2000","unstructured":"Rauch F, Travers R, Parfitt AM, Glorieux FH (2000) Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26:581\u2013589","journal-title":"Bone"},{"key":"3723_CR103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrendo.2015.71","volume":"11","author":"IR Reid","year":"2015","unstructured":"Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11:418\u2013428","journal-title":"Nat Rev Endocrinol"},{"key":"3723_CR104","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13023-015-0362-2","volume":"10","author":"LL Tosi","year":"2015","unstructured":"Tosi LL, Oetgen ME, Floor MK et al (2015) Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis 10:146","journal-title":"Orphanet J Rare Dis"},{"key":"3723_CR105","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3109\/14767058.2016.1151870","volume":"29","author":"DP Yimgang","year":"2016","unstructured":"Yimgang DP, Shapiro JR (2016) Pregnancy outcomes in women with osteogenesis imperfecta. J Matern Fetal Neonatal Med 29:2358\u20132362","journal-title":"J Matern Fetal Neonatal Med"},{"key":"3723_CR106","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cge.12409","volume":"87","author":"RM Patel","year":"2015","unstructured":"Patel RM, Nagamani SC, Cuthbertson D et al (2015) A cross-sectional multicenter study of osteogenesis imperfecta in North America\u2014results from the linked clinical research centers. Clin Genet 87:133\u2013140","journal-title":"Clin Genet"},{"key":"3723_CR107","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","volume":"91","author":"F Rauch","year":"2006","unstructured":"Rauch F, Munns C, Land C, Glorieux FH (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268\u20131274","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-016-3723-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T18:06:24Z","timestamp":1718733984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-016-3723-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":107,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3723"],"URL":"https:\/\/doi.org\/10.1007\/s00198-016-3723-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]}}}